Lupus vaccine study: which pneumonia shot works best?
NCT ID NCT00611663
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This study tested two different pneumococcal vaccination strategies in 47 adults with stable lupus. One group received a prime-boost approach with a conjugate vaccine followed by a polysaccharide vaccine six months later; the other got a placebo then the standard polysaccharide vaccine. The goal was to see which strategy produced a stronger immune response without worsening lupus symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC Vaccinologie - Hopital Cochin
Paris, 75679, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pneumococcal vaccines (Prevenar and Pneumo23)
What this could lead to
If successful, this could identify a safer, more effective vaccination schedule for lupus patients to prevent serious pneumococcal infections.
What could go wrong
This is a small, completed trial with only 47 participants, so results may not apply to all lupus patients. The vaccines might not boost immunity enough or could trigger lupus flares.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.